GLP-1 Drugs Reduce Addiction Risk: New Study on Ozempic-Like Medications

What Are GLP-1 Receptor Agonists and How Do They Work?

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that mimic the action of the naturally occurring hormone GLP-1, which is released in the gut in response to eating. These drugs, such as semaglutide (found in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), were first developed to treat type 2 diabetes by improving blood sugar control and later gained fame for their weight loss effects in obesity management. By activating GLP-1 receptors in the pancreas, brain, and other tissues, they slow gastric emptying, increase insulin secretion, and reduce appetite signals, leading to significant weight reduction—often 15% or more of body weight in clinical trials.

In Australia, these medications have seen rapid uptake, with prescriptions surging amid the obesity epidemic affecting over 30% of adults. Universities like Monash and the Florey Institute have been at the forefront of researching their broader applications, including potential roles beyond metabolic health.

The Landmark Study Linking GLP-1 Drugs to Lower Addiction Risks

A groundbreaking cohort study published in the BMJ in early 2026 examined electronic health records from over 606,000 US veterans with type 2 diabetes, comparing those initiating GLP-1 receptor agonists to those starting sodium-glucose cotransporter-2 (SGLT2) inhibitors. Using target trial emulation—a method that mimics randomized controlled trials in observational data—the researchers analyzed risks over three years.

Key findings revealed that GLP-1 initiators without prior substance use disorders (SUDs) had a 14% overall reduced risk of developing new SUDs (hazard ratio [HR] 0.86, 95% CI 0.83-0.88). Specific reductions included 18% for alcohol use disorder, 14% for cannabis, 20% for cocaine and nicotine, and 25% for opioids. For those with existing SUDs, benefits were even more pronounced: 26% fewer hospital admissions, 31% fewer emergency visits, 39% fewer overdoses, and 50% lower mortality from SUDs.

Australian addiction psychiatrist Associate Professor Shalini Arunogiri from Monash University highlighted the study's implications in The Conversation, noting its relevance despite the US veteran cohort (mostly older males). She emphasized that while associations are promising, causation requires randomized trials.

Mechanisms: How GLP-1 Drugs Target the Brain's Reward System

GLP-1 receptors are abundant in brain regions like the nucleus accumbens and ventral tegmental area, key to reward processing and addiction. These drugs appear to dampen dopamine release triggered by addictive substances, reducing cravings and reinforcing effects. Preclinical animal studies, many conducted at Australian institutions like the Florey Institute, show GLP-1 agonists decrease consumption of alcohol, nicotine, cocaine, and opioids by blunting reward signals.

Step-by-step, the process involves: 1) Drug binding to central GLP-1 receptors; 2) Inhibition of dopamine neurons; 3) Reduced motivation for drug-seeking; 4) Lower intake and relapse risk. Human neuroimaging supports this, showing decreased striatal activity during craving cues.

This mechanism offers hope for a unified addiction treatment, unlike current substance-specific therapies.

Australian Universities Pioneering GLP-1 Research for Addiction

While the BMJ study used US data, Australian higher education institutions are actively exploring GLP-1's anti-addiction potential. At Monash University, researchers like A/Prof Arunogiri analyze global data for local applicability. The Florey Institute has reviewed over 30 preclinical studies showing consistent reductions in drug reward.

Griffith University led the COaST trial, where semaglutide induced 14.6% weight loss in clozapine-treated schizophrenia patients—many with comorbid addiction risks—without worsening psychosis. The University of Queensland reported similar success, positioning GLP-1 as vital for metabolic issues in mental health.

• Florey Institute: Synthesizing GLP-1 analogs to address global shortages.
• Monash: Commentary on broad SUD prevention.
• Griffith/UQ: Trials in high-risk psychiatric populations.

Evidence from Australian and Global Trials: Promising but Preliminary

Beyond observationals, small RCTs support GLP-1's role. A Griffith-led 36-week trial (n=small) showed semaglutide superior to placebo for antipsychotic weight gain, indirectly aiding addiction-prone groups. Globally, a JAMA Psychiatry RCT found semaglutide reduced heavy drinking in AUD patients.

In Australia, ANZCTR lists GLP-1 trials for obesity in mental health, with addiction as secondary outcomes. Experts at the University of Sydney, like Dr James Bell, stress integrating GLP-1 with behavioral therapies.

Real-world Australian data shows rising GLP-1 use, with PBS subsidies for diabetes expanding access.

Photo by Fotos on Unsplash

Implications for Addiction Treatment in Australia

Australia faces high SUD rates: 21% lifetime alcohol disorder, rising opioids post-COVID. GLP-1 could fill gaps, especially for polysubstance use where no single drug works. For Indigenous communities and rural areas, oral formulations like Rybelsus offer accessibility.

Stakeholders: NDARC at UNSW advocates trials; Turning Point (Monash) explores integration. Cost-effectiveness: GLP-1's obesity benefits may offset SUD savings, per modeled VA data.

Cultural context: Stigma hinders treatment; GLP-1's diabetes/weight framing could boost uptake.

Challenges, Side Effects, and Limitations

• Gastrointestinal issues (nausea 20-30%).
• Rare pancreatitis, gallbladder risks—monitor in AUD patients.
• Observational bias; veteran cohort limits generalizability.
• Long-term data needed; adherence drops after 1 year.

Australian unis like Flinders warn of reproductive risks in young women. Balanced prescribing essential.

Ongoing Research and University-Led Initiatives

Australian universities drive innovation: Florey develops cheaper GLP-1 synthesis; UQ/Griffith expand psychiatric trials. ANZCTR trials test GLP-1 in AUD.

Future: Phase III RCTs, combination therapies. Funding via NHMRC prioritizes addiction-metabolic links.

Expert Perspectives from Australian Academics

A/Prof Arunogiri (Monash): "First medication promising across substances." Dr Bell (USyd): "Builds on existing treatments." Florey experts: "Brain reward modulation key."

Multi-perspective: Optimism tempered by need for diverse trials including women, youth.

Future Outlook: Transforming Addiction Care Down Under

By 2030, GLP-1 could integrate into Australian SUD guidelines, reducing healthcare burden ($10B+ annually). Universities gear up: Monash/Florey lead trials, training researchers.

Actionable insights: Patients discuss with GPs; academics pursue research assistant jobs in neuropharmacology.

Optimistic horizon: Personalized medicine via GLP-1 variants from AU labs.

Photo by Fotos on Unsplash

Career Opportunities in GLP-1 and Addiction Research

Australia's unis seek experts: higher ed jobs in pharmacology, psychiatry. Explore rate my professor for mentors, career advice for PhDs. Postdocs at Florey/Monash abound.

Internal links to drive traffic: university jobs, Australia listings.